Literature DB >> 23257672

[Long-term remission of Langerhans cell sarcoma by AIM regimen combined with involved-field irradiation].

Ikuo Shimizu1, Wataru Takeda, Takehiko Kirihara, Keijiro Sato, Yuko Fujikawa, Toshimitsu Ueki, Masahiko Sumi, Mayumi Ueno, Naoaki Ichikawa, Hikaru Kobayashi, Masahide Watanabe, Takeshi Uehara, Shigeo Nakamura.   

Abstract

A 67-year-old woman presented with a right inguinal mass in May 2006. CT scan showed lymph node involvement from the right inguinal to the common iliac and (18)F-FDG-PET revealed uptake in those areas. Biopsy results indicated Langerhans cell sarcoma (LCS). Interestingly, tumor cells expressed a high MIB1 index of 30%. We administered doxorubicin, ifosfamide, and mesna (AIM) chemotherapy, which were reported to effectively treat soft tissue sarcoma. After 5 courses of AIM therapy and involved-field radiation for residual diseases and a relapsed lesion on her right cervical node, she has remained in complete remission for more than 4 years. LCS is an intractable malignant disease and the optimal therapeutic strategy remains unclear. The AIM regimen combined with radiation therapy may be an effective treatment option for this disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257672

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

1.  Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review.

Authors:  Yaonan Zhang; Zongyang Qu; Fang Fang
Journal:  Oncol Lett       Date:  2016-09-27       Impact factor: 2.967

2.  Epstein-Barr Virus-Positive Langerhans Cell Sarcoma: Is There a Link? A Case Report.

Authors:  Yu Guo; Shui-Hong Zhou; Zai-Zai Cao; Yang-Yang Bao; Li-Fang Shen; Hong-Tian Yao
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.